GSK vs. RGC: A Head-to-Head Stock Comparison

Updated on August 29, 2025

Here’s a clear look at GSK and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

GSK trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RGC is a standard domestic listing.

Symbol	GSK	RGC
Company Name	GSK plc	Regencell Bioscience Holdings Limited
Country	United Kingdom	Hong Kong
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	80.40 billion USD	7.04 billion USD
Exchange	NYSE	NasdaqCM
Listing Date	March 28, 1980	July 16, 2021
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of GSK and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

GSK vs. RGC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	GSK	RGC
5-Day Price Return	1.24%	9.89%
13-Week Price Return	1.48%	-8.07%
26-Week Price Return	2.23%	12,218.18%
52-Week Price Return	-11.02%	6,352.38%
Month-to-Date Return	3.63%	2.65%
Year-to-Date Return	9.13%	10,323.08%
10-Day Avg. Volume	4.90M	0.21M
3-Month Avg. Volume	6.79M	2.15M
3-Month Volatility	24.77%	642.26%
Beta	0.96	2.34

Profitability

Return on Equity (TTM)

GSK

24.18%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 24.18% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RGC

-54.75%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

GSK vs. RGC: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

GSK

10.82%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

GSK’s Net Profit Margin of 10.82% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

RGC

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

Net Profit Margin data for RGC is currently unavailable.

GSK vs. RGC: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

GSK

16.22%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

GSK’s Operating Profit Margin of 16.22% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

RGC

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

Operating Profit Margin data for RGC is currently unavailable.

GSK vs. RGC: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

Symbol	GSK	RGC
Return on Equity (TTM)	24.18%	-54.75%
Return on Assets (TTM)	5.77%	-51.38%
Net Profit Margin (TTM)	10.82%	--
Operating Profit Margin (TTM)	16.22%	--
Gross Profit Margin (TTM)	71.77%	--

Financial Strength

Current Ratio (MRQ)

GSK

0.87

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

GSK’s Current Ratio of 0.87 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RGC

42.68

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

GSK vs. RGC: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

GSK

1.17

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.17. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

RGC

0.00

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

GSK vs. RGC: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

GSK

2.37

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

In the lower quartile for the Pharmaceuticals industry, GSK’s Interest Coverage Ratio of 2.37 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

RGC

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

Interest Coverage Ratio data for RGC is currently unavailable.

GSK vs. RGC: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

Symbol	GSK	RGC
Current Ratio (MRQ)	0.87	42.68
Quick Ratio (MRQ)	0.57	41.89
Debt-to-Equity Ratio (MRQ)	1.17	0.00
Interest Coverage Ratio (TTM)	2.37	--

Growth

Revenue Growth

GSK vs. RGC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

GSK vs. RGC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

GSK

4.26%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

With a Dividend Yield of 4.26%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

RGC

0.00%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

GSK vs. RGC: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

GSK

54.01%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

GSK’s Dividend Payout Ratio of 54.01% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RGC

0.00%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

GSK vs. RGC: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

Symbol	GSK	RGC
Dividend Yield (TTM)	4.26%	0.00%
Dividend Payout Ratio (TTM)	54.01%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

GSK

17.09

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

GSK’s P/E Ratio of 17.09 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RGC

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

P/E Ratio data for RGC is currently unavailable.

GSK vs. RGC: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

GSK

1.85

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

GSK’s P/S Ratio of 1.85 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

P/S Ratio data for RGC is currently unavailable.

GSK vs. RGC: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

GSK

3.84

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

GSK’s P/B Ratio of 3.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

RGC

9.57

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

GSK vs. RGC: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

Symbol	GSK	RGC
Price-to-Earnings Ratio (TTM)	17.09	--
Price-to-Sales Ratio (TTM)	1.85	--
Price-to-Book Ratio (MRQ)	3.84	9.57
Price-to-Free Cash Flow Ratio (TTM)	12.54	--